Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)

Eligibility criteria:
Inclusion Criteria:

          -  Institutionalized people in nurswing homes since the beginning of the COVID19 epidemic
             who do not have the infection present at the time of entering into the study.

          -  Healthcare professionals who provide direct care (nursing assistants and registered
             nurses) to institutionalized older people in nursing homes with confirmed cases of
             COVID19 during the past 8 days.

          -  Subjects that give their consent to participate in the study or that it be obtained
             from their representative / legal guardian.

        Exclusion Criteria:

          -  Staff members who do not provide direct care to residents.

          -  Residents with active SARS-CoV-2 infection present, or with symptoms compatible with
             COVID19 confirmed by PCR test.

          -  Staff members with present or past SARS-CoV-2 infection, or with PCR-confirmed
             symptoms consistent with COVID19.

          -  History of QT interval prolongation or arrhythmias of any etiology.

          -  Presence of retinopathy of any etiology, changes in acuity or visual field.

          -  Severe hearing loss (requires the use of hearing aids).

          -  Structural heart disease.

          -  History of non-structural heart failure, ischemic heart disease, SCASEST, or SCACEST

          -  Chronic liver disease.

          -  Alcoholism.

          -  Epilepsy.

          -  For the participating professionals, pregnancy or suspected pregnancy (if they are
             planning pregnancy, or in fertilizer treatment, they must abandon the study).

          -  Subjects with known HDQ hypersensitivity.

          -  Subjects diagnosed with G6PDH deficiency.

          -  Taking other medicines that prolong QT: domperidone, ondansetron, cilostazol,
             antiarrhythmics (procainamide, amiodarone, flecainide, sotalol), macrolides
             (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin,),
             moxofloxacin,) neuroleptics (haloperidol, chlorpromazine, pimozide), antidepressants
             (citalopram, escitalopram), sulpiride, anticholinesterase drugs (donepezil)

          -  Denial to participate in the study
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Eligibility (NLI label): Contradiction